All About Pitavastatin: Ten Questions And Answers
Abstract
N/A
Keywords:
N/A
Downloads
Download data is not yet available.
References
1 Catapano AL. Pitavastatin - pharmacological profile from early phase studies. Atherosclerosis Supplements, 2010; 11:3-7 https://doi.org/10.1016/S1567-5688(10)71063-1 PMid:21193152
2 Luo Z, Zhang Y, Gu J, Feng P, Wang Y. Pharmacokinetic properties of single- and multiple-dose pitavastatin calcium tablets in healthy chinese volunteers. Ther Res Clin Exp, 2015; 77:52-57 https://doi.org/10.1016/j.curtheres.2015.02.001 PMid:26082816 PMCid:PMC4460194
3 Baker W, Chamberlin K. Benefit\risk assessment of pitavastatin for the treatment of hypercholesterolemia in older patients. Clin Interv Aging, 2015; 10:733 https://doi.org/10.2147/CIA.S67532 PMid:25931816 PMCid:PMC4404990
4 Adams SP, Alaeiilkhchi N, Wright JM Pitavastatin for lowering lipids Cochrane Database Syst Rev. 2020; 6 https://doi.org/10.1002/14651858.CD013673 PMCid:PMC7387836
5,Tokgözoglu L, Zamorano JL Current perspectives on the use of statins in the treatment of dyslipidaemic patients: focus on pitavastatin. Drugs Context. 2020; 9:2020-4-4 https://doi.org/10.7573/dic.2020-4-4 PMid:32587627 PMCid:PMC7295107
6 Jeong IK, Kim SR Efficacy and Safety of Pitavastatin in a Real-World Setting: Observational Study Evaluating SaFety in Patient Treated with Pitavastatin in Korea (PROOF Study). Endocrinol Metab (Seoul). 2020 Dec; 35(4):882-891 https://doi.org/10.3803/EnM.2020.723 PMid:33261312 PMCid:PMC7803594
7 Fici F, Tarim B A, Faikoglu G et al Review article: Pitavastatin: Similarities And Differences Compared With Other Statins Acta Pharm. Sci. 2021; 59:(4). https://doi.org/10.23893/1307-2080.APS.05935
8 Stender S, Budinski D, Gosho M, Hounslow N. Pitavastatin shows greater lipid lowering efficacy over 12 weeks than pravastatin in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia. Eur J Prev Cardiol, 2013; 20:40-53 https://doi.org/10.1177/2047487312451251 PMid:22679249
9 Gumprecht J, Gosho M, Budinski D, Hounslow N. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia. Diabetes, Obesity and Metabolism, 2011; 13:1047-1055, https://doi.org/10.1111/j.1463-1326.2011.01477.x PMid:21812889
10 Taguchi I, Iimuro S, Iwata H, et al. High-dose versus low-dose pitavastatin in Japanese patients with stable coronary artery disease (REAL-CAD) a randomized superiority trial. Circ, 2018; 137:1997-2009 https://doi.org/10.1161/CIRCULATIONAHA.117.032615 PMid:29735587 PMCid:PMC5959207
11Suh SY, Rha SW, Ahn TH et al. Long-term safety and efficacy of pitavastatin in patients with acute myocardial infarction (from the Livalo acute myocardial infarction study LAMIS ). Am J Cardiol, 2011; 108:1530-1535 https://doi.org/10.1016/j.amjcard.2011.07.009 PMid:21890083
12 Moroi M, Nagayama D, Hara F, et al. Outcome of pitavastatin versus atorvastatin therapy in patients with hypercholesterolemia at high risk for atherosclerotic cardiovascular disease. Int J Cardiol, 2020; 305:139-146 https://doi.org/10.1016/j.ijcard.2020.01.006 PMid:31987664
13 Teramoto T, Shimano H, Yokote K, Urashima M. New evidence on pitavastatin: Efficacy and safety in clinical studies, Expert Opin Pharmacother, 2010; 11: 817-828, 14 Pirillo A, Catapano AL. Pitavastatin and HDL: Effects on plasma levels and function(s). Atheroscler Suppl, 2017; 27:e1-9 https://doi.org/10.1517/14656561003641990 PMid:20201733
15 Kurogi K, Sugiyama S, Sakamoto K, et al. Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary artery disease: The COMPACT-CAD study. J Cardiol, 2013; 62:87-94. https://doi.org/10.1016/j.jjcc.2013.03.008 PMid:23672789
16 Thakker D, Nair S, Pagada A, et al. Statin use and the risk of developing diabetes: a network meta-analysis. Pharmacoepidemiol Drug Saf, 2016; 25:1131-1149 https://doi.org/10.1002/pds.4020 PMid:27277934
17 Casula M, Mozzanica F, Scotti L, et al Statin use and risk of new-onset diabetes: A meta-analysis of observational studies. Nutr Metab Cardiovasc Dis, 2017; 27:396-406 https://doi.org/10.1016/j.numecd.2017.03.001 PMid:28416099
18 Arnaboldi L, Corsini A. Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin. Atherosclerosis Supplements, 2015; 16: 1-27 https://doi.org/10.1016/S1567-5688(14)70002-9 PMid:25575403
19 Chapman MJ, Orsoni A, Robillard P et al Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: Insights from the CAPITAIN and PREVAIL-US studies. Curr Med Res Opin, 2014; 30:775-784 https://doi.org/10.1185/03007995.2013.874989 PMid:24328357
20 Vallejo-Vaz AJa. Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes. Atherosclerosis, 2015; 241:409-418 https://doi.org/10.1016/j.atherosclerosis.2015.06.001 PMid:26074315
21 Cui JY, Zhou RR, Han S, et al Statin therapy on glycemic control in type 2 diabetic patients: A network meta-analysis. J Clin Pharm Ther, 2018; 43:556-570 https://doi.org/10.1111/jcpt.12690 PMid:29733433
22 Bahar Arican Tarim, Francesco Fici, Istemihan Tengiz et al Do statins counteract the effect of antidiabetic drugs? Results of the SCEAD study Yonsei Med J 2023; 64:175-180 https://doi.org/10.3349/ymj.2022.0287 PMid:36825343 PMCid:PMC9971433
23 Maruyama T, Takada M, Nishibori Y, et al. Comparison of preventive effect on cardiovascular events with different statins- The CIRCLE Study. Circ J. 2011; 75:1951-9 https://doi.org/10.1253/circj.CJ-10-1163 PMid:21673458
24 Francesco Fici, Gokhan Faikoglu, Bahar Arican Tarim et al Pitavastatin: Coronary Atherosclerotic Plaques Changes and Cardiovascular Prevention High Blood Pressure and Cardiovascular Prevention 2022; 29:137-144 https://doi.org/10.1007/s40292-021-00496-0 PMid:35064911
25 Hiro T, Kimura T. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol. 2009; 54:293-302 https://doi.org/10.1016/j.jacc.2009.04.033 PMid:19608026
26 Matsushita K, Hibi K, Komura N, et al. Effects of 4 statins on regression of coronary plaque in acute coronary syndrome. Circ J. 2016; 80:1634-43. https://doi.org/10.1253/circj.CJ-15-1379 PMid:27264413
27 Toi T, Taguchi I, Yoneda S, et al. Early effect of lipid-lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque-comparison with atorvastatin. Circ J. 2009; 73:1466-72, https://doi.org/10.1253/circj.CJ-08-1051 PMid:19531899
28 Kodama K, Komatsu S, Ueda Y, et al. Stabilization and regression of coronary plaques treated with pitavastatin proven by angioscopy and intravascular ultrasound: The TOGETHAR trial. Circ J. 2010; 74:1922-8 https://doi.org/10.1253/circj.CJ-10-0038 PMid:20625215
29 Hattori K, Ozaki Y, Ismail TF, et al. Impact of statin therapy on plaque characteristics as assessed by serial OCT, grayscale and integrated backscatter-IVUS. Am Coll Cardiol Imaging. 2012; 5:169-77 https://doi.org/10.1016/j.jcmg.2011.11.012 PMid:22340823
30 Kubo T, Imanishi T, Takarada S, et al. Implication of plaque color classification for assessing plaque vulnerability: a coronary angioscopy and optical coherence tomography investigation. JACC Cardiovasc Interv. 2008; 1:74-80 https://doi.org/10.1016/j.jcin.2007.11.001 PMid:19393149
31Navarese EP, Kowalewski M, Andreotti F, et al. Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol. 2014; 113:1753-6 https://doi.org/10.1016/j.amjcard.2014.02.034 PMid:24792742
32 Gili S, Iannaccone M, Colombo F, et al. Effects of statins on plaque rupture assessed by optical coherence tomography in patients presenting with acute coronary syndromes: insights from the optical coherence tomography (OCT)-FORMIDABLE registry. Eur Heart J Cardiovasc Imaging. 2018; 19:524-31 https://doi.org/10.1093/ehjci/jex102 PMid:28605473
33 Goliasch G, Winter MP, Ayoub M, et al. A contemporary definition of periprocedural myocardial injury after percutaneous coronary intervention of chronic total occlusions. JACC Cardiovasc Interv. 2019; 12:1915-23 https://doi.org/10.1016/j.jcin.2019.06.053 PMid:31601387
34 Lampropoulos K, Megalou A, Bazoukis G et al Pre-loading therapy with statins in patients with angina and acute coronary syndromes undergoing PCI J Interv Cardiol 2017; 30:507-51 https://doi.org/10.1111/joic.12421 PMid:28786142
35 Nishiguchi T, Kubo T, Tanimoto T, et al. Effect of early pitavastatin therapy on coronary fibrous-cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome. The ESCORT study. JACC Cardiovasc Imaging. 2018; 11:829-38 https://doi.org/10.1016/j.jcmg.2017.07.011 PMid:28917689
36 Kurihara Y, Douzono T, Kawakita K, er al A Large−scale, Long−term, Prospective Post−marketing Surveillance of Pitavastatin 2008; 36: 709-731
37 Saito Y Critical appraisal of the role of pitavastatin in treating dyslipidemia and achieving lipid goals Vascular Health and Risk Management 2009:5 921-936 https://doi.org/10.2147/VHRM.S5551 PMid:19997573 PMCid:PMC2788597
38 Corsini A, Ceska R. Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel?. Curr Med Res Opin, 2011; 27:1551-1562 https://doi.org/10.1185/03007995.2011.589433 PMid:21682551
39 Gosho M, Tanahashi M, Hounslow N, et al. Pitavastatin therapy in polymedicated patients is associated with a low risk of drug-drug interactions: analysis of real-world and phase 3 clinical trial data. Int J Clin Pharmacol Ther 2015; 53:635-46 https://doi.org/10.5414/CP202195 PMid:26104032
40 Michael Schachter. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005 Feb; 19(1):117-25. https://doi.org/10.1111/j.1472-8206.2004.00299.x PMid:15660968
2 Luo Z, Zhang Y, Gu J, Feng P, Wang Y. Pharmacokinetic properties of single- and multiple-dose pitavastatin calcium tablets in healthy chinese volunteers. Ther Res Clin Exp, 2015; 77:52-57 https://doi.org/10.1016/j.curtheres.2015.02.001 PMid:26082816 PMCid:PMC4460194
3 Baker W, Chamberlin K. Benefit\risk assessment of pitavastatin for the treatment of hypercholesterolemia in older patients. Clin Interv Aging, 2015; 10:733 https://doi.org/10.2147/CIA.S67532 PMid:25931816 PMCid:PMC4404990
4 Adams SP, Alaeiilkhchi N, Wright JM Pitavastatin for lowering lipids Cochrane Database Syst Rev. 2020; 6 https://doi.org/10.1002/14651858.CD013673 PMCid:PMC7387836
5,Tokgözoglu L, Zamorano JL Current perspectives on the use of statins in the treatment of dyslipidaemic patients: focus on pitavastatin. Drugs Context. 2020; 9:2020-4-4 https://doi.org/10.7573/dic.2020-4-4 PMid:32587627 PMCid:PMC7295107
6 Jeong IK, Kim SR Efficacy and Safety of Pitavastatin in a Real-World Setting: Observational Study Evaluating SaFety in Patient Treated with Pitavastatin in Korea (PROOF Study). Endocrinol Metab (Seoul). 2020 Dec; 35(4):882-891 https://doi.org/10.3803/EnM.2020.723 PMid:33261312 PMCid:PMC7803594
7 Fici F, Tarim B A, Faikoglu G et al Review article: Pitavastatin: Similarities And Differences Compared With Other Statins Acta Pharm. Sci. 2021; 59:(4). https://doi.org/10.23893/1307-2080.APS.05935
8 Stender S, Budinski D, Gosho M, Hounslow N. Pitavastatin shows greater lipid lowering efficacy over 12 weeks than pravastatin in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia. Eur J Prev Cardiol, 2013; 20:40-53 https://doi.org/10.1177/2047487312451251 PMid:22679249
9 Gumprecht J, Gosho M, Budinski D, Hounslow N. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia. Diabetes, Obesity and Metabolism, 2011; 13:1047-1055, https://doi.org/10.1111/j.1463-1326.2011.01477.x PMid:21812889
10 Taguchi I, Iimuro S, Iwata H, et al. High-dose versus low-dose pitavastatin in Japanese patients with stable coronary artery disease (REAL-CAD) a randomized superiority trial. Circ, 2018; 137:1997-2009 https://doi.org/10.1161/CIRCULATIONAHA.117.032615 PMid:29735587 PMCid:PMC5959207
11Suh SY, Rha SW, Ahn TH et al. Long-term safety and efficacy of pitavastatin in patients with acute myocardial infarction (from the Livalo acute myocardial infarction study LAMIS ). Am J Cardiol, 2011; 108:1530-1535 https://doi.org/10.1016/j.amjcard.2011.07.009 PMid:21890083
12 Moroi M, Nagayama D, Hara F, et al. Outcome of pitavastatin versus atorvastatin therapy in patients with hypercholesterolemia at high risk for atherosclerotic cardiovascular disease. Int J Cardiol, 2020; 305:139-146 https://doi.org/10.1016/j.ijcard.2020.01.006 PMid:31987664
13 Teramoto T, Shimano H, Yokote K, Urashima M. New evidence on pitavastatin: Efficacy and safety in clinical studies, Expert Opin Pharmacother, 2010; 11: 817-828, 14 Pirillo A, Catapano AL. Pitavastatin and HDL: Effects on plasma levels and function(s). Atheroscler Suppl, 2017; 27:e1-9 https://doi.org/10.1517/14656561003641990 PMid:20201733
15 Kurogi K, Sugiyama S, Sakamoto K, et al. Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary artery disease: The COMPACT-CAD study. J Cardiol, 2013; 62:87-94. https://doi.org/10.1016/j.jjcc.2013.03.008 PMid:23672789
16 Thakker D, Nair S, Pagada A, et al. Statin use and the risk of developing diabetes: a network meta-analysis. Pharmacoepidemiol Drug Saf, 2016; 25:1131-1149 https://doi.org/10.1002/pds.4020 PMid:27277934
17 Casula M, Mozzanica F, Scotti L, et al Statin use and risk of new-onset diabetes: A meta-analysis of observational studies. Nutr Metab Cardiovasc Dis, 2017; 27:396-406 https://doi.org/10.1016/j.numecd.2017.03.001 PMid:28416099
18 Arnaboldi L, Corsini A. Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin. Atherosclerosis Supplements, 2015; 16: 1-27 https://doi.org/10.1016/S1567-5688(14)70002-9 PMid:25575403
19 Chapman MJ, Orsoni A, Robillard P et al Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: Insights from the CAPITAIN and PREVAIL-US studies. Curr Med Res Opin, 2014; 30:775-784 https://doi.org/10.1185/03007995.2013.874989 PMid:24328357
20 Vallejo-Vaz AJa. Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes. Atherosclerosis, 2015; 241:409-418 https://doi.org/10.1016/j.atherosclerosis.2015.06.001 PMid:26074315
21 Cui JY, Zhou RR, Han S, et al Statin therapy on glycemic control in type 2 diabetic patients: A network meta-analysis. J Clin Pharm Ther, 2018; 43:556-570 https://doi.org/10.1111/jcpt.12690 PMid:29733433
22 Bahar Arican Tarim, Francesco Fici, Istemihan Tengiz et al Do statins counteract the effect of antidiabetic drugs? Results of the SCEAD study Yonsei Med J 2023; 64:175-180 https://doi.org/10.3349/ymj.2022.0287 PMid:36825343 PMCid:PMC9971433
23 Maruyama T, Takada M, Nishibori Y, et al. Comparison of preventive effect on cardiovascular events with different statins- The CIRCLE Study. Circ J. 2011; 75:1951-9 https://doi.org/10.1253/circj.CJ-10-1163 PMid:21673458
24 Francesco Fici, Gokhan Faikoglu, Bahar Arican Tarim et al Pitavastatin: Coronary Atherosclerotic Plaques Changes and Cardiovascular Prevention High Blood Pressure and Cardiovascular Prevention 2022; 29:137-144 https://doi.org/10.1007/s40292-021-00496-0 PMid:35064911
25 Hiro T, Kimura T. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol. 2009; 54:293-302 https://doi.org/10.1016/j.jacc.2009.04.033 PMid:19608026
26 Matsushita K, Hibi K, Komura N, et al. Effects of 4 statins on regression of coronary plaque in acute coronary syndrome. Circ J. 2016; 80:1634-43. https://doi.org/10.1253/circj.CJ-15-1379 PMid:27264413
27 Toi T, Taguchi I, Yoneda S, et al. Early effect of lipid-lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque-comparison with atorvastatin. Circ J. 2009; 73:1466-72, https://doi.org/10.1253/circj.CJ-08-1051 PMid:19531899
28 Kodama K, Komatsu S, Ueda Y, et al. Stabilization and regression of coronary plaques treated with pitavastatin proven by angioscopy and intravascular ultrasound: The TOGETHAR trial. Circ J. 2010; 74:1922-8 https://doi.org/10.1253/circj.CJ-10-0038 PMid:20625215
29 Hattori K, Ozaki Y, Ismail TF, et al. Impact of statin therapy on plaque characteristics as assessed by serial OCT, grayscale and integrated backscatter-IVUS. Am Coll Cardiol Imaging. 2012; 5:169-77 https://doi.org/10.1016/j.jcmg.2011.11.012 PMid:22340823
30 Kubo T, Imanishi T, Takarada S, et al. Implication of plaque color classification for assessing plaque vulnerability: a coronary angioscopy and optical coherence tomography investigation. JACC Cardiovasc Interv. 2008; 1:74-80 https://doi.org/10.1016/j.jcin.2007.11.001 PMid:19393149
31Navarese EP, Kowalewski M, Andreotti F, et al. Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol. 2014; 113:1753-6 https://doi.org/10.1016/j.amjcard.2014.02.034 PMid:24792742
32 Gili S, Iannaccone M, Colombo F, et al. Effects of statins on plaque rupture assessed by optical coherence tomography in patients presenting with acute coronary syndromes: insights from the optical coherence tomography (OCT)-FORMIDABLE registry. Eur Heart J Cardiovasc Imaging. 2018; 19:524-31 https://doi.org/10.1093/ehjci/jex102 PMid:28605473
33 Goliasch G, Winter MP, Ayoub M, et al. A contemporary definition of periprocedural myocardial injury after percutaneous coronary intervention of chronic total occlusions. JACC Cardiovasc Interv. 2019; 12:1915-23 https://doi.org/10.1016/j.jcin.2019.06.053 PMid:31601387
34 Lampropoulos K, Megalou A, Bazoukis G et al Pre-loading therapy with statins in patients with angina and acute coronary syndromes undergoing PCI J Interv Cardiol 2017; 30:507-51 https://doi.org/10.1111/joic.12421 PMid:28786142
35 Nishiguchi T, Kubo T, Tanimoto T, et al. Effect of early pitavastatin therapy on coronary fibrous-cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome. The ESCORT study. JACC Cardiovasc Imaging. 2018; 11:829-38 https://doi.org/10.1016/j.jcmg.2017.07.011 PMid:28917689
36 Kurihara Y, Douzono T, Kawakita K, er al A Large−scale, Long−term, Prospective Post−marketing Surveillance of Pitavastatin 2008; 36: 709-731
37 Saito Y Critical appraisal of the role of pitavastatin in treating dyslipidemia and achieving lipid goals Vascular Health and Risk Management 2009:5 921-936 https://doi.org/10.2147/VHRM.S5551 PMid:19997573 PMCid:PMC2788597
38 Corsini A, Ceska R. Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel?. Curr Med Res Opin, 2011; 27:1551-1562 https://doi.org/10.1185/03007995.2011.589433 PMid:21682551
39 Gosho M, Tanahashi M, Hounslow N, et al. Pitavastatin therapy in polymedicated patients is associated with a low risk of drug-drug interactions: analysis of real-world and phase 3 clinical trial data. Int J Clin Pharmacol Ther 2015; 53:635-46 https://doi.org/10.5414/CP202195 PMid:26104032
40 Michael Schachter. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005 Feb; 19(1):117-25. https://doi.org/10.1111/j.1472-8206.2004.00299.x PMid:15660968
Crossmark
Statistics
202 Views | 54 Downloads
How to Cite
1.
Fici F, Faikoglu G, Saygisever-Faikoglu K, Uskur T, Berk B, Yillar DO. All About Pitavastatin: Ten Questions And Answers. JDDT [Internet]. 15Sep.2023 [cited 2Oct.2023];13(9):1-. Available from: https://jddtonline.info/index.php/jddt/article/view/5960
Section
Letter to Editor
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.